Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome
Open accessThe DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index, and 2 are not checked yet.
Abstract
Objective: Possibly due to a deficiency of insulin mediators, polycystic ovary syndrome (PCOS) is often associated with insulin resistance (IR) and hyperinsulinemia, likely responsible for an elevated production of reactive oxygen species. We investigated oxidative-related alterations in erythrocytes and anti-inflammatory effects of inositol in women with PCOS before and after treatment with myo-inositol (MYO). Methods: Twenty-six normal-weight PCOS patients were investigated before and after MYO administration (1200 mg/day for 12 weeks;n=18) or placebo (n=8) by evaluating serum testosterone, serum androstenedione, fasting serum insulin, fasting serum glucose, insulin area under the curve (AUC), and glucose AUC after oral glucose tolerance test and homeostasis model of assessment–IR. In erythrocytes, band 3 tyrosine phosphorylation (Tyr-P) level, glutathione (GSH) content, and glutathionylated proteins (GSSP) were also assessed. Results: Data show that PCOS patients' erythrocytes underwent oxidative stress as indicated by band 3 Tyr-P values, reduced cytosolic GSH content, and increased membrane protein glutathionylation. MYO treatment significantly improved metabolic and biochemical parameters. Significant reductions were found in IR and serum values of androstenedione and testosterone. A significant association between band 3 Tyr-P levels and insulin AUC was found at baseline but disappeared after MYO treatment, while a correlation between band 3 Tyr-P and testosterone levels was detected both before and after MYO treatment. Conclusions: PCOS patients suffer from a systemic inflammatory status that induces erythrocyte membrane alterations. Treatment with MYO is effective in reducing hormonal, metabolic, and oxidative abnormalities in PCOS patients by improving IR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Twenty studies compared MI alone at doses of 1 to 4 g daily either alone or in combination with FA 200 to 400 mcg daily (25-27, 30-34, 41, 42, 44, 46-55) against the comparators of metformin, FA alone, or placebo.”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [32]
The cited source says what the claim attributes to it.
In the citing paper
“Three studies were placebo controlled (32, 35, 43).”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [32]
The cited source says what the claim attributes to it.
In the citing paper
“One study (n = 26) (32) comparing 1200 mg MI to matched placebo powder for 12 weeks in women with BMI <25 kg/m2 with high risk of bias reported lower body weight (−1.83 kg ± 1.86 vs +0.25 kg ± 0.71, P = 0.0055), BMI (−0.69 kg/m2 ± 0.69 vs +0.09 kg/m2 ± 0.27, P = .0058), testosterone (−0.35 nmol/L ± 0.24 vs −0.01 nmol/L ± 0.29, P = .0043), androstenedione (−3.96 nmol/L ± 2.16 vs +0.28 mol/L ± 0.39,”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [32]
In the citing paper
“In particular, several studies have confirmed the role of MYO and DCI as insulin sensitizers, improving both metabolic and oxidative imbalance [54].”
From Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism (2022) · cites this paper as [54]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Contribution of myo-inositol to reproduction
Papaleo, E., Unfer, V., Baillargeon, J., & Chiu, T. T. Y. (2009) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2009.09.008 · Cited by 88
RetractedStatistical power analysis for the behavioral sciences
(1990) · Computers, Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,269
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Tietze, F. (1969) · Analytical Biochemistry · doi:10.1016/0003-2697(69)90064-5 · Cited by 6,047
(1996) · Institutional Research Information System University of Turin (University of Turin) · doi:10.1111/j · Cited by 5,486
Men at risk: occupation and male infertility
Claman, P. (2004) · Fertility and Sterility · doi:10.1016/s0015-0282(03)01188-9 · Cited by 2,387
Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967
Diamanti‐Kandarakis, E., Kouli, C., Bergiele, A. T., Filandra, F. A., Tsianateli, T. C., Spina, G., Zapanti, E. D., & Bartzis, M. I. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.11.4006 · Cited by 1,110
STADTMAN, E. R., & LEVINE, R. L. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06187.x · Cited by 1,007
Research works printed but not linked: 4
- Gerli, 2003, European review for medical and pharmacological sciences, 7, 151
- 1994, 107, 99
- Carlomagno, 2011, European review for medical and pharmacological sciences, 15, 931
- 2008, METABOLISM CLINICAL AND EXPERIMENTAL, 10, 1390
Cited by
Murri, M., Luque-Ramírez, M., Insenser, M., Ojeda-Ojeda, M., & Escobar-Morreale, H. F. (2013) · Human Reproduction Update · doi:10.1093/humupd/dms059 · Cited by 655
“Of these 34 studies, 28 were excluded for the following reasons: (i) not relevant for the research question (25 studies); (ii) non-strict diagnosis of PCOS (Dincer et al., 2001); (iii) studies not showing the glutathione concentrations of the control group (Taskin et al., 1999; Dona et al., 2012).”
BackgroundArmanini, D., Boscaro, M., Bordin, L., & Sabbadin, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084110 · Cited by 324
“In particular, several studies have confirmed the role of MYO and DCI as insulin sensitizers, improving both metabolic and oxidative imbalance [54].”
BackgroundSelf-citationMyo-Inositol and Its Derivatives: Their Emerging Role in the Treatment of Human Diseases
Chhetri, D. R. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01172 · Cited by 192
Greff, D., Juhász, A. E., Váncsa, S., Váradi, A., Sipos, Z., Szinte, J., Park, S., Hegyi, P., Nyirády, P., Ács, N., et al. (2023) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-023-01055-z · Cited by 143
González, F., Nair, K. S., Daniels, J. K., Basal, E., Schimke, J. M., & Blair, H. E. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1259 · Cited by 130
Metadata
- Authors
- Donà, G., Sabbadin, C., Fiore, C., Bragadin, M., Giorgino, F. L., Ragazzi, E., Clari, G., Bordin, L., & Armanini, D.
- Affiliations
- University of Padua (IT)
- Ca' Foscari University of Venice (IT)
- Corresponding author
- Bordin, Luciana
- Armanini, Decio
- ORCID
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-04
- Volume
- 166
- Issue
- 4
- Pages
- 703-710
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2135069653
- Cited by
- 89
- References
- 49
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 7 · 2023: 9 · 2022: 9 · 2021: 10 · 2020: 7 · 2019: 9 · 2018: 5 · 2017: 11 · 2016: 5 · 2015: 2 · 2014: 1 · 2013: 3 · 2012: 1
- FWCI
- 2.61
- Type
- journal article
- Language
- en
- Open access
- green
- www.scopus.com
- Licence
- other-oa
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- ARCA (Università Ca' Foscari Venezia) (submittedVersion, other-oa)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
- Health Sciences › Medicine › Biochemistry (medical) › Antioxidant Activity and Oxidative Stress
- Keywords
- polycystic ovary syndrome, myo-inositol, oxidative stress, erythrocytes, insulin resistance, hyperinsulinemia, glutathione, glutathionylation, reactive oxygen species, testosterone, androstenedione, systemic inflammation
- MeSH terms
- Adult, Blood Glucose, Drug Administration Schedule, Erythrocyte Count, Erythrocytes, Female, Humans, Inositol, Insulin, Insulin Resistance, Placebos, Polycystic Ovary Syndrome, Down-Regulation, Oxidative Stress, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome. https://app.cochat.ai/papers/10.1530/eje-11-0840
- The paper
- Donà, G., Sabbadin, C., Fiore, C., Bragadin, M., Giorgino, F. L., Ragazzi, E., Clari, G., Bordin, L., & Armanini, D. (2012). Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome. European Journal of Endocrinology. https://doi.org/10.1530/eje-11-0840
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.